The International Myeloma Foundation Says IMNOVID® (Pomalidomide), The Newest Medication For Advanced Cases Of Multiple Myeloma, Is Approved For Reimbursement In Sweden, Spain, And Switzerland

NORTH HOLLYWOOD, Calif.--(BUSINESS WIRE)--The International Myeloma Foundation (IMF) says IMNOVID® (pomalidomide), called POMALYST® in the US, is now approved for reimbursement in Sweden, Spain, and Switzerland, with decisions expected to follow in more countries in Europe. Myeloma, also called multiple myeloma, is a cancer of cells in the bone marrow that typically requires multiple treatments used in sequence. Marketing authorization for IMNOVID was granted in Europe in August 2013 for use in patients after all previous treatments have failed. These new decisions mean patients in these three countries will now have access to this therapeutic through their government health programs.

Help employers find you! Check out all the jobs and post your resume.